O-Methylated Metabolite of 7,8-Dihydroxyflavone Activates TrkB Receptor and Displays Antidepressant Activity

Xia Liu, Emory University
Qi Qi, Emory University
Ge Xiao, Ctr Dis Control & Prevent
Jingyu Li, Harvard University
Hongbo R. Luo, Harvard University
Keqiang Ye, Emory University

Journal Title: Pharmacology
Volume: Volume 91, Number 3-4
Publisher: Karger Publishers | 2013-01-01, Pages 185-200
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1159/000346920
Permanent URL: https://pid.emory.edu/ark:/25593/rmvbz

Final published version: http://dx.doi.org/10.1159/000346920

Copyright information:
© 2013, Karger Publishers
Accessed January 24, 2019 12:54 AM EST
O-Methylated Metabolite of 7,8-Dihydroxyflavone Activates TrkB Receptor and Displays Antidepressant Activity

Xia Liu, Qi Qi, Ge Xiao, Jingyu Li, Hongbo R. Luo, and Keqiang Ye

Abstract

7,8-Dihydroxyflavone (7,8-DHF) acts as a TrkB receptor-specific agonist. It mimics the physiological actions of brain-derived neurotrophic factor (BDNF) and demonstrates remarkable therapeutic efficacy in animal models of various neurological diseases. Nonetheless, its in vivo pharmacokinetic profiles and metabolism remain unclear. Here we report that 7,8-DHF and its O-methylated metabolites distribute in mouse brain after oral administration. Both hydroxy groups can be mono-methylated, and the mono-methylated metabolites activate TrkB in vitro and in vivo. Blocking methylation, using COMT inhibitors, diminishes the agonistic effect of TrkB activation by 7,8-DHF or 4′-dimethylamino-7,8-DHF, supporting the contribution of the methylated metabolite to TrkB activation in mouse brain. Moreover, we have synthesized several methylated metabolite derivatives, and they also potently activate the TrkB receptor and reduce immobility in both forced swim test and tail suspension test, indicating that these methylated metabolites may possess antidepressant activity. Hence, our data demonstrate that 7,8-DHF is orally bioavailable and can penetrate the brain-blood barrier. The O-methylated metabolites are implicated in TrkB receptor activation in the brain.

Keywords
TrkB agonist; Brain-derived neurotrophic factor; Synthetic derivatives; Antidepressant; Neurogenesis

Introduction

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family, and exerts its biological functions on neurons predominantly through the TrkB receptor tyrosine kinase [1, 2]. Although BDNF/TrkB signaling is traditionally thought of in terms of synaptic plasticity and neuroprotection [3, 4], accumulating evidence indicates that these molecules

Keqiang Ye, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322 (USA), kye@emory.edu.
are also critical for antidepressant drug efficacy. Accumulating evidence supports the neurotrophin hypothesis in depression. For instance, antidepressant treatment induces BDNF mRNA expression, as well as autophosphorylation and activation of TrkB in the brain [5, 6], and the behavioral effects of antidepressants in the forced swim test (FST) are attenuated in mice with only one active BDNF allele (BDNF +/- mice), completely lacking BDNF specifically in forebrain or expressing a dominant negative form of TrkB (trkB. T1) [6, 7]. Ablation of TrkB specifically in hippocampal neural progenitor cells prevents chronic antidepressant-induced neurogenesis and renders the mice behaviorally nonresponsive to chronic antidepressant treatment [8]. Combined, these results suggest a model whereby chronic antidepressant treatment induces BDNF expression and long-term activation of TrkB, leading to increased neurogenesis and an antidepressant effect [9–11].

We have recently reported that 7,8-dihydroxyflavone (7,8-DHF) acts as a TrkB agonist, which selectively binds to the extracellular domain of TrkB, but not TrkA, and stimulates its dimerization and autophosphorylation [12]. Most recently, it has been shown that 7,8-DHF mimics BDNF and dampens the stressful event-induced development of the ‘depressive’ phenotype [13]. Interestingly, chronic treatment with 7,8-DHF enhances neurogenesis in the dentate gyrus and demonstrates robust antidepressant effects. In addition, blocking TrkB inhibits the antidepressant effect of 7,8-DHF [14]. These findings allow us to hypothesize that 7,8-DHF may exert its antidepressant effect by directly activating TrkB receptors in the hippocampus. Although it takes a few weeks for orally administrated 7,8-DHF to exert its antidepressant effect, subchronic intraperitoneal injection of 7,8-DHF also significantly decreases immobility in FST. However, acute injection of 7,8-DHF has no effect on the latency of immobility [14]. Although oral administration or intraperitoneal injection of 7,8-DHF displays impressive therapeutic efficacy on various BDNF/TrkB-implicated neurological diseases in animal models, its in vivo pharmacokinetic profiles and metabolism remain unknown. Catechol-containing compounds usually have a short in vivo half-life; they are prone to be cleared in the circulatory system and undergo oxidation, glucuronidation, sulfation or methylation. For instance, apomorphine, which contains a catechol group, is a nonnarcotic morphine derivative that acts as a potent dopaminergic agonist. Apomorphine metabolism occurs through several enzymatic pathways, including N-demethylation, sulfation, glucuronidation, and catechol-O-methyltransferase (COMT)-catalyzed oxidation as well as by nonenzymatic oxidation [15]. COMT is involved in the inactivation of the catecholamine neurotransmitters. The enzyme transfers a methyl group to the catecholamine from the methyl donor, S-adenosyl methionine. The compounds with a catechol structure, like catechol estrogens and catechol-containing flavonoids, are substrates of COMT.

The main objectives of this study are to explore the in vivo pharmacokinetics/metabolism of 7,8-DHF and identify its main metabolites in the brain and its potential functions. In this report, we show that 7,8-DHF has a half-life of about 134 min in plasma after oral gavage of 50 mg/kg of the drug. 7,8-DHF and its O-methylated metabolites are detectable in mouse brain with T_max at 10 min and C_max of 70 ng/ml. Interestingly, the methylated metabolite swiftly activates TrkB in primary neurons and mouse brain. In addition, inhibition of methylation by blocking COMT reduces the TrkB stimulatory effect by 7,8-DHF. Also, the
O-methylated metabolite and synthetic methoxy-flavone derivatives exhibit a prominent antidepressant effect.

Experimental Procedures

Cells, Reagents, and Mice

BDNF was from Roche. Anti-p-TrkB 817 was from Epitomics. Anti-TrkB antibody was from Cell Signaling. Wild-type C57BL/6 mice were bred in a pathogen-free environment in accordance with Emory Medical School guidelines. All chemicals not included above were purchased from Sigma. 7,8-DHF was purchased from TCI. The flavonoids were from Indofine (Hillsborough, N.J., USA): NMR spectrum (Bruker AV300K, 300 MHz), MS spectrum (Shimadzu LCMS), HPLC (PE, dual pumper, SPD detector, ODS-C18 reverse phase, 254 nm, CH₃CN-H₂O-0.1% TFA). Phospho-TrkB Y816 antibody was raised against [H]-CKLQNLAKASPV-pY-LDILG-[OH] (aa 806–822) (EM437 and EM438) as rabbit polyclonal antibody at Covance. The antiserum was purified by affinity column chromatography. This phospho-TrkB was utilized for immunoblotting and immunostaining the brain sections [14]. Mouse monoclonal anti-TrkB (BD Biosciences, San Jose, Calif., USA) was used for immunostaining. p-Akt 473 Sandwich ELISA was from Cell Signaling. Anti-phospho-Akt-473, anti-Akt, and anti-phospho-Erk1/2 antibodies were from Cell Signaling.

Primary Rat Cortical Neuron Culture

Cortical primary neurons were dissected from an E18 embryo and cultured, and the cortex was extirpated, cross-chopped and suspended by gently pipetting for separation in DMEM containing 5% fetal calf serum and 5% horse serum. The cell suspension was then centrifuged at 250 g for 5 min. This operation was repeated again. Cells were seeded into polyethyleneimine-coated 10-cm dishes and 12-well plates including coated coverslips and incubated at 37°C in 5% CO₂/95% air. After 3 h, culture medium was changed to Neurobasal containing B-27 supplement (Invitrogen) and incubated for 4 days. For maintenance, half the medium was changed to fresh Neurobasal/B-27 every 4 days. After 1 week, the cultured neurons were used in drug treatment experiments.

Forced Swim Test

The FST assay is routinely performed in our lab. The experiment was conducted as previously described [14]. Adult male mice (2–3 months old) were randomly submitted to an FST without a preswim. Saline and methylated derivatives (5 mg/kg, 250 μl) were orally administrated by gavage for 21 days. The mice were allowed to adapt to the test room for 2 days. They were placed in a clear glass cylinder with a diameter of 16 cm, half-filled with clear water at 24°C (water depth of 14 cm, and the mice were not allowed to reach the bottom of the cylinder; water was changed after each mouse) for a total of 6 min (with 2 min of preswim), and immobility was recorded during the last 4 min by an investigator blind to the genotype and treatment.
**Tail Suspension Test**

Among 3 well-established behavioral assays [FST, tail suspension test (TST), and learned helplessness] to examine the antidepressant effect, TST is a well-accepted and easy depression-like behavioral experimental paradigm [16]. Briefly, adult male mice (2–3 months old) were treated with saline and methylated derivatives (5 mg/kg) via oral gavage for 21 days. The total duration of immobility induced by tail suspension was measured according to the method described [17]. After chronic drug treatment, both acoustically and visually isolated mice were suspended 50 cm above the floor by adhesive tape placed approximately 1 cm from the tip of the tail. Mice were considered immobile only when they hung passively and completely motionless. Immobility time was manually recorded during a 6-min period by an experienced observer. The observer was in the room where experiments were performed and was blind to the condition of the animals.

**Neurogenesis Analysis in TrkB Agonist-Treated Hippocampus**

Adult male mice (2–3 months old) were orally administered with saline, compound C, D and 7-methoxy-8-hydroxyflavone (H428; 5 mg/kg) for 21 days. Then BrdU (50 mg/kg) was intraperitoneally injected. Within 2 h, the mice were perfused with 4% paraformaldehyde. Immunohistochemical staining was performed on formalin-fixed paraffin-embedded sections. Sections of the brain were cut, deparaffinized in xylene, and rehydrated in graded alcohols. The slides were boiled in 10 mmol/l citric acid (pH 6.0) for 10 min, followed by incubation in 2 N HCl for 10 min at room temperature. The slides were then permeabilized and blocked with 1% BSA in 0.2% PBS Tween 20. The incorporated BrdU was stained using anti-BrdU-FITC (Abcam, USA, 1: 50) at 4°C overnight. After three washes in PBS, the cells were stained with DAPI for another 10 min at room temperature. The slides were finally mounted with AquaMount (Lerner Laboratories, USA) containing 0.01% 1,4-diazobicyclo (2,2,2)octane and examined under a fluorescent microscope.

**Immunohistochemistry Staining**

Brain tissues were fixed in 4% paraformaldehyde overnight followed by paraffin embedding.

Sections of 6 μm were cut. For immunohistochemical staining, brain sections were deparaffinized in xylene and rehydrated in graded alcohols. Endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 5 min and all slides were boiled in 10 mmol/l sodium citrate buffer (pH 6.0) for 10 min. Phosphorylated TrkB816 and TrkB were detected using specific antibodies. Paraffin sections were deparaffinized in xylene and rehydrated gradient ethanol solution. Samples were boiled in 10 mmol/l sodium citrate buffer for 20 min to retrieve antigen. Brain sections were incubated with anti-TrkB (BD Biosciences) 1: 50, p-TrkB 1: 200 dilution at 4°C overnight. After washing with PBS 3 times, TrkB and phosphorylated TrkB816 were detected using specific primary antibodies and the Zymed Histo-SP AEC kit. Slides were then counterstained with hematoxylin.

**In vivo Pharmacokinetic Study (CRO by Cerep, Inc.)**

Two-month-old male CD-1 mice (20–30 g) were obtained from Charles River Laboratories. The mice were divided into two groups: vehicle control and 7,8-DHF. 7,8-DHF was
dissolved in water and 50 mg/kg of the dose was administered orally. Each animal was subjected to one blood draw and one brain collection. We had 3-, 10-, 30-, 60-, 120-, 240-, 360- and 480-min time points with 3 mice at each time point. For fasting, food but not water was withheld for at least 3–4 h. Following fasting, each mouse was weighed and the dose was calculated according to body weight. After administration of a test compound, food but not water was withheld for a further 1–2 h. Blood was collected via cardiac puncture. Blood aliquots (300–400 μl) were collected in tubes coated with lithium heparin, mixed gently, then kept on ice and centrifuged at 2,500 g for 15 min at 4°C within 1 h of collection. The plasma was harvested and kept frozen at −20°C until further processing. The brain sample was rinsed with cold saline, weighed, and kept on ice until further processing within 1 h of collection. Each brain was homogenized in 1.5 ml cold PBS for 10 min on ice using Power Gen 125. The brain homogenate from each brain was then stored at −20°C until further processing. The following are standard procedures for the HPLC-LC/MS/MS.

Statistics

Statistical analyses were performed using either Student’s t test or one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison tests versus controls by the computer program GraphPad Prism (GraphPad Software, USA). Results were expressed as mean ± SEM and were considered as significant when p < 0.05.

Organic Synthesis of Compound C and Compound D

The compounds were synthesized following the methods described in our previous publication [14].

Preparation of Compound 2—To the solution of compound 1 (2.0 g, 10.98 mmol, 1.0 Eq) in DMF (20 ml) Li₂CO₃ (1.22 g, 16.47 mmol, 1.5 Eq) and BnBr (2.25 g, 13.18 mmol, 1.2 Eq) were added. It was stirred at 60°C overnight. TLC and LC/MS showed that BnBr reacted with the two free OH groups. Two regioisomers and a bibenzylated product were formed. The Li₂CO₃ was filtered off and the solvent was removed under reduced pressure, after which water was added and extracted with EA 2 times. The organic phase was dried, filtered and concentrated. It was purified by a column chromatography for 1.1 g of crude product (containing some of the dibenylated product, ¹H NMR showed the desired product should be 70%) (lot No. MC0707-43-1): ¹H NMR (400 MHz, DMSO-d₆): δ 12.56 (br s, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.31–7.37 (m, 9H), 6.69 (d, J = 9.2 Hz, 1H), 5.08 (s, 1H), 5.00 (s, 1H), 4.95 (s, 2H), 3.90 (s, 1H), 3.88 (s, 3H), and 2.59 (s, 3H).

Preparation of Compound 3—To the solution of compound 2 (800 mg, 2.06 mmol, 1.0 Eq) in DCM (10 ml) 4-(pyrrolidin-1-yl)benzoic acid (550 mg, 2.88 mmol, 1.4 Eq), DCC (1,270 mg, 6.16 mmol, 3.0 Eq) and DMAP (750 mg, 6.15 mmol, 3.0 Eq) were added. It was stirred at room temperature overnight. TLC and LC/MS showed the reaction was complete. It was purified by a column chromatography (PE:EA = 5: 1 to 3: 1) for about 600 mg of the desired product (lot No.: MC0707-044-A) [MS-ESI: calculated 445.2; found 446.2 (M+1)⁺].

Preparation of Compound 4 To the solution of compound 3 (500 mg, 1.12 mmol, 1.0 Eq) in DMSO (10 ml) NaOH (225 mg, 5.62 mmol, 5.0 Eq) was added. It was stirred at room
temperature for 2 h. TLC and LC/MS showed the reaction was completed. It was quenched with water and extracted with EA 3 times, then the combined EA phase was evaporated under reduced pressure after most EA was removed, water was added, the product was collected by filtration and dried to get 350 mg of the desired product (lot No.: MC0707-045-1) [MS-ESI: calculated 445.2; found 444.1 (M–1), 446.2 (M+1)].

Preparation of Compound C To the solution of compound 4 (250 mg, 0.56 mmol, 1.0 Eq) in AcOH (10 ml) H$_2$SO$_4$ (0.1 ml) was added. It was refluxed for 1 h. TLC and LC/MS showed the reaction was complete. The solvent was removed under reduced pressure, water was added, the product was collected by filtration, and washed with water and methanol to get 120 mg of the desired product with 96% HPLC purity (lot No.: MC0707-046-A) [MS-ESI: calculated 337.1; found 338.4 (M+1), HPLC: 96%].

Preparation of Compound 6—To the solution of compound 5 (12 g, 70 mmol, 1.0 Eq) in DMF (180 ml) Li$_2$CO$_3$ (5.9 g, 70 mmol, 1.0 Eq) was added. Then 1-(bro-momethyl)benzene (11.7 ml, 1 mol) was added dropwise. The solution was stirred at 60°C overnight under N$_2$. TLC showed the reaction was complete. It was quenched with water and extracted with EA. The organic phase was dried, filtered, and concentrated. The residue was purified by column chromatography to get 5.4 g of the desired product (lot No.: MC0707-1-1, yield: 29%): $^1$HNMR (400 MHz, CDCl$_3$): $\delta$ 12.51 (br s, 1H), 7.34–7.44 (m, 5H), 7.26 (d, J = 8.0 Hz, 1H), 6.53 (d, J = 8.8 Hz, 1H), 5.23 (s, 1H), 5.24 (s, 2H), 2.56 (s, 3H).

Preparation of Compound 7—To the solution of compound 6 (4.4 g, 1.0 Eq) in acetone (140 ml) K$_2$CO$_3$ (14.1 g, 6.0 Eq) and (MeO)$_2$SO$_4$ (1.39 g, 0.5 Eq) were added. The reaction mixture was stirred at 5°C overnight. TLC showed the starting material and the desired product. It was quenched with water and extracted with EA. The organic phase was dried, filtered and concentrated. It was purified by column chromatography to get 1.1 g of the crude product (lot No.: MC0707-9-2) [MS-ESI: calculated 419.2; found 420.5 (M+1)].

Preparation of Compound 8—To the solution of compound 7 (1.0 g, 1.0 Eq) in THF (50 ml) t-BuOK (907.6 mg, 8.09 mmol, 2.2 Eq) was added at 0°C. Then the mixture was stirred for 30 min and 4-(dimethylamino)benzoyl chloride (742.7 mg, 4.04 mmol, 1.1 Eq.) in THF (8 ml) was added. It was stirred for 3 h. LC/MS showed the reaction was complete. It was quenched with water and extracted with EA. The organic phase was dried, filtered and concentrated. The residue was purified by column chromatography to get 1.1 of the crude product (lot No.: MC0707-23-1) [MS-ESI: calculated 419.2; found 420.4 (M+1)].

Preparation of Compound 9—To the solution of compound 8 (780 mg, 1.0 Eq) in DMSO (5 ml) NaOH (370 mg, 5.0 Eq) was added. It was stirred for 1 h. LC/MS showed the reaction was complete. The two batches were combined together and it was quenched with water. The pH was adjusted to 5–6. It was extracted with EA. The organic phase was concentrated and purified by column chromatography to get 550 mg of the crude product (lot No.: MC0707-23-1) [MS-ESI: calculated 419.2; found 420.4 (M+1)].
Preparation of Compound D—To the solution of compound 9 (500 mg, 1.0 Eq) in AcOH (10 ml) concentrated H$_2$SO$_4$ (0.1 ml) was added. It was refluxed for 1 h. LC/MS showed the reaction was complete. It was quenched with water. It was extracted with EA. The organic phase was dried, filtered, and concentrated. The residue was purified by column chromatography to get about 110 mg of compound D (lot No.: MC0707-28-1): $^1$HNMR (400 MHz, DMSO-d$_6$): 8 10.46 (s, 1H), 7.89 (d, J = 9.2 Hz, 2H), 7.60 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 9.2 Hz, 2H), 6.69 (s, 1H), 3.94 (s, 3H), 3.03 (s, 6H) [MS-ESI: calculated 311.1; found 312.2 (M+1)$^+$, HPLC: 98.4%].

Results

In vivo Pharmacokinetic Profiling and Metabolite Identification

Catechol group-containing compounds, such as catecholamine neurotransmitters, levodopa, and flavonoids, are subjected to extensive metabolic modification that includes conjugation (glucuronidation, sulfation, and methylation) and oxidation, leading to their low bioavailability and poor pharmacokinetic profiles. Oral administration of 7,8-DHF or its synthetic derivative 4′-dimethylamino-7,8-DHF (4′-DMA-7,8-DHF) evidently activates the TrkB receptor in mouse brain at 2 or 4 h and exhibits prominent antidepressant activity, which suggests a stimulatory effect on TrkB by either the compounds themselves or by their metabolites [14]. Therefore, we investigated 7,8-DHF in vivo pharmacokinetic profiles (after oral administration) at a 50 mg/kg dosage, which is 10-fold the widely used therapeutic dose. We chose this high dose in order to quantitatively obtain brain concentrations of the drug and its metabolites at late time points. Mouse plasma and brain samples were collected at different time points (3, 10, 30, 60, 120, 240, 360 and 480 min), subjected to acetonitrile precipitation, and analyzed by HPLC-MS/MS. Several major metabolites including 7-methoxy-8-hydroxy-flavone (7M8H-flavone) and two unknown peaks were detected in addition to the parent drug. The plasma 7,8-DHF concentration peaked at 10 min with 70 ng/ml, and brain 7,8-DHF also peaked at 10 min with a concentration of 50 ng/g of brain. 7,8-DHF in plasma was still detectable even at 8 h (5 ng/ml). However, in the brain, approximately 7 ng/g of 7,8-DHF was found at 4 h and it was below the quantitative limit at 6 h. The 7-position methylated metabolite (7M8H-flavone) was detected as early as after 3 min in the plasma. Its concentration was maximal at 10 min with 1.0 ng/ml, and it decreased to 0.2 ng/ml at 4 h. It was below the quantitative limit at 6 h. We failed to detect this metabolite in mouse brain at any time (fig. 1). The $T_{1/2}$ for 7,8- DHF is 134 min with $AUC_{last}$ of 6,500 min-ng/ml and $AUC_{inf}$ of 7,515 min-ng/ml. The in vivo pharmacokinetic profiles are summarized in table 1. In addition, we also monitored 7,8-DHF and Caco-2 permeability of its synthetic lead 4′-DMA-7,8-DHF, which is a good predictor of human oral bioavailability. The apparent permeabilities $P_{app}$ for these two compounds are listed in table 2. Notably, the addition of the dimethylamino group on the 4′-position of the B ring increased the efflux of the lead compound, indicating a reduction of oral bioavailability.

Identification of the Methylated Metabolites in Plasma and Mouse Brain

In order to identify the other metabolites, we conducted LC/MS/MS with the plasma samples at 30 min. Full scan HPLC-MS analysis was performed and total ion current
chromatograms from the test and control samples were compared. Retention times, peak areas, and the respective MS spectra of the species detected in the test samples, but not in the control samples, were identified and recorded. The retention time on HPLC for the authentic metabolite H428 was 2.8 min. The identities of the compounds with retention times of 2.92 and 2.66 min remained unclear (fig. 2 a). In order to get more information about the chemical structure of the additional peaks, a product ion scan was performed. The 2.66-min peak had a broad, uneven profile and its elution time was earlier than in the tandem MS analysis; also, no product ions were observed in the spectrum. Based on this observation and the fact that a similarly intense, broad peak was seen in the control plasma sample, the 2.66-min peak was attributed to the matrix itself and was not thought to be related structurally to 7,8-DHF or H428. Since the product ion spectrum of the standard (H428) and the 2.92-min peak from numerous mouse samples were very similar, and the molecular weight was the same, 268 (m/z 269), we concluded that this peak represented the other methylated isomer, 7-hydroxy-8-methoxyflavone (fig. 2 b–d). In addition to these two methylated metabolites, we also observed the extracted ion chromatogram at 431 m/z, which corresponds to the M + H + 176 m/z glucuronidated product of 7,8-DHF in the plasma but not in the brain (online suppl. fig. 1; for all online suppl. material, see www.karger.com/doi/10.1159/000346920). Hence, 7,8-DHF can be methylated as well as conjugated, by glucuronidation, in vivo after oral dosing of 50 mg/kg of 7,8-DHF in mice. 7,8-DHF and its methylated metabolites can penetrate the brain-blood barrier (BBB).

The Metabolite, 7M8H-Flavone, Activates the TrkB Receptor in Primary Neurons and Mouse Brain

To explore whether the methylated metabolite could activate the TrkB receptor in primary neurons, we compared the mono-methylated H428 and dimethylated 7,8-DHF (D024) with their 4′-DMA-7,8-DHF counterparts. As we previously reported, 4′-DMA-7,8-DHF displayed more robust TrkB agonistic activity than 7,8-DHF. We made a similar observation for 4′-DMA-H428 versus H428. Interestingly, the dimethylated derivatives also somehow triggered TrkB activation (fig. 3 a, b). BDNF was included as a positive control for validating TrkB activation in primary neurons by the lead compound (fig. 3 b, lower panels). To assess whether the methylated H428 could trigger TrkB activation in mouse brain, we treated C57BL/6J mice with 5 mg/kg of various compounds via oral gavage. The brain samples were collected 2 h after drug treatment. Immunoblotting analysis demonstrated that both 7,8-DHF and H428 clearly activated the TrkB receptor compared to vehicle control. The dimethylated 7,8-DHF (D024) also elicited TrkB activation (p-TrkB Y816), but the effect was not as strong as that of the other two compounds (fig. 3 c, top panel). However, p-TrkB 706 immunoblotting demonstrated that D024 elicited the strongest p-TrkB signal (fig. 3 c, 2nd panel). The p-Akt ELISA assay showed that the downstream Akt signal was activated by these compounds as well (fig. 3 c, bottom panel). We conducted the same experiments with 4′-DMA-7,8-DHF derivatives with oral dosing of 1 mg/kg. We observed a similar trend of p-TrkB activation in brain lysates (fig. 3 d, top panel). Both 4′-DMA-7,8-DHF and its mono-methylated derivative potently activated Akt, whereas the dimethylated derivative failed to do so (fig. 3 d, bottom panel). Therefore, the 7-methylated metabolite of 7,8-DHF activates TrkB signaling in primary neurons and mouse brain.

Pharmacology. Author manuscript; available in PMC 2016 March 16.
Inhibition of COMT Reduces TrkB Activation by 7,8-DHF or 4′-DMA-7,8-DHF

To ascertain whether COMT is responsible for the methylation of 7,8-DHF, we employed two COMT inhibitors that include tolcapone and entacapone, which are commonly used in the treatment of Parkinson’s disease [18]. The optimal dose schedule for these two inhibitors has previously been extensively studied in rodents [19, 20]. Following the experimental schemes, we pretreated mice with 30 mg/kg of the two inhibitors via oral gavage 1 h before 7,8-DHF or 4′-DMA-7,8-DHF administration, since this has been reported as a favorable dosage for COMT inhibitors [21]. Two hours after flavonoid treatment, we collected the brain samples and analyzed TrkB signaling. As expected, both 7,8-DHF and 4′-DMA-7,8-DHF obviously activated TrkB compared to vehicle control. Interestingly, entacapone and tolcapone alone clearly elevated TrkB phosphorylation compared to vehicle control (fig. 4 a, left panels lanes 4 and 7 vs. lane 1). Notably, in the presence of entacapone or tolcapone, TrkB activation by the flavonoids was not as strong as the agonists alone (lanes 5, 6 and 8, 9 vs. lanes 2, 3), indicating COMT inhibitor pretreatment blocked TrkB activation by 7,8-DHF or 4′-DMA-7,8-DHF. The downstream p-Akt immunoblotting tightly correlated with the upstream p-TrkB status (fig. 4 a, 3rd left panel). Since 30 mg/kg of COMT inhibitors alone triggered TrkB phosphorylation and shadowed the agonistic effect by two small agonists, we lowered the dose of the inhibitors to 10 mg/kg to reduce their effect on TrkB activation. We found entacapone at 10 mg/kg was still able to diminish the agonistic effect by 4′-DMA-7,8-DHF, whereas tolcapone lost its inhibitory activity in suppressing TrkB phosphorylation by these two small agonists (fig. 4 a, middle and right panels). p-Akt ELISA analysis also confirmed our observation in the immunoblotting assay. There are no significant changes between control versus 7,8-DHF or 4′-DMA-7,8-DHF in both the entacapone-treated and tolcapone-treated groups (fig. 4 b). Hence, methylation of 7,8-DHF might mediate the agonistic effect of 7,8-DHF in mice.

7M8H-Flavone and Synthetic O-Methylated Derivatives Display Antidepressant Effects

To explore whether the methylated derivatives also possess the agonistic effect, we synthesized several 4′-position substitute derivatives and examined their TrkB stimulatory effect on primary neurons. The organic synthetic routes are summarized in figure 5 a. Oral administration of two compounds at a 1 mg/kg dosage robustly triggered TrkB activation in mouse brain 2 h after drug treatment (fig. 5 b). FST and TST are well established behavioral assays used to examine antidepressant effects. We have shown that both 7,8-DHF and its lead compound 4′-DMA-7,8-DHF robustly decreased the immobility in FST after chronic treatment [14]. To investigate whether these methylated derivatives possess any antidepressant effect, we conducted a chronic experiment by consecutively treating the mice with 5 mg/kg of drugs for 21 days (orally, once a day). In an FST assay, all three compounds significantly reduced the immobility with H428 exhibiting the strongest effect (fig. 5 c, left panel). In a TST assay, both H428 and compound C substantially decreased the immobility, whereas compound D lowered the immobility, but the reduction was not statistically significant (fig. 5 c, right panel). Notably, acute drug treatment had no effect on immobility, which is different from traditional SSRI or tricyclic antidepressants (data not shown). Moreover, we monitored locomotor activity after 3 weeks of drug treatment, and found compound D significantly increased the locomotor activity compared to vehicle control or H428, compound C (fig. 5 d). Presumably, compound D might reduce immobility by...
increasing the locomotor activity. Thus, the 7-methylated H428 and compound C activate the TrkB receptor and display a prominent antidepressant effect.

7M8H-Flavone and Synthetic O-Methylated Derivatives Activate TrkB and Enhance Neurogenesis in the Hippocampus

BDNF is capable of enhancing neurogenesis; intra-hippocampal infusion of BDNF into the hippocampus of adult rats increases the production of new neurons [22] and chronic (but not acute) antidepressant administration increases BDNF expression and neurogenesis. To examine whether chronic treatment with the methylated derivatives regulates neurogenesis, we conducted a BrdU incorporation assay by intraperitoneally injecting BrdU 2 h before sacrificing the animals. We found 3 weeks of drug treatment, with both H428 and compound C, significantly promoted neurogenesis compared to vehicle, whereas compound D also elevated neurogenesis but the result was not statistically significant (fig. 6 a, b). Immunohistochemistry staining with p-TrkB and total TrkB antibodies also demonstrated that both H428 and compound C strongly provoked TrkB phosphorylation in the dentate gyrus in the hippocampus. Nonetheless, the p-TrkB signal by compound D was not as strong as those of H428 and compound C (fig. 6 c). Hence, chronic treatment with methylated derivatives enhanced TrkB activation and triggered neurogenesis in the hippocampus.

Discussion

In the current report, we show that 7,8-DHF can penetrate the BBB and its major metabolites in plasma are O-mono-methylated and O-glucuronidated metabolites. In the brain, 7,8-DHF and one mono-methylated metabolite (7-hydroxy-8-methoxyflavone) are also detected. Interestingly, blockage of COMT with two different inhibitors reduces the TrkB stimulatory activity by 7,8-DHF or the lead compound 4′-DMA-7,8-DHF in mouse brain, indicating that the methylated metabolites contribute to TrkB receptor activation upon oral administration of 7,8-DHF. Interestingly, the methylated metabolite H428 activates the TrkB receptor in primary neurons and in mouse brain after oral administration, underscoring the observation that methylated metabolites trigger TrkB receptor activation. As expected, chronic treatment with the methylated metabolite H428 or its synthetic derivatives for 3 weeks significantly reduces the immobility in two types of antidepressant behavioral assays, which were accompanied with evident TrkB phosphorylation in the hippocampus and demonstrable neurogenesis. These observations support the notion that the active methylated metabolite induces chronic TrkB activation and prominent neurogenesis, leading to a robust antidepressant effect.

Since oral administration of 7,8-DHF or its synthetic derivative 4′-DMA-7,8-DHF provokes TrkB activation at 1–2 h and the stimulatory effect is demonstrable even at 4 h in mouse brain, we investigated its in vivo pharmacokinetic profiles. The Cmax of 7,8-DHF in plasma peaked at 10 min with 70 ng/ml, but it slowly decreased to 24 ng/ml at 4 h, and even at 8 h, 5 ng/ml of 7,8-DHF was detected, indicating that it is orally bioavailable. Although its bioavailability is low, it is metabolized at a much slower pace when its concentration is low. On the other hand, both the methylated metabolite concentrations are relatively low compared to the parent 7,8-DHF, suggesting that glucuronidation but not methylation may
be the main metabolism. Interestingly, the 8-methoxy-metabolite possesses a 148-min half-life versus 92 min for 7-methoxy-metabolite in plasma, indicating that 8-methoxy-7-hydroxyflavone is more metabolically stable than 8-hydroxy-7-methoxyflavone (H428). In brain samples, 7,8-DHF also peaks at 10 min with about 52 ng/g of brain, and decreases to 18 ng/g at 30 min, after which it remains relatively stable until 240 min (7 ng/g). Surprisingly, the 7-methoxy-metabolite (H428) is below the limit of quantification in the brain, whereas the 8-methoxy-metabolite is observable as early as 3 min after oral administration and detectable even at 240 min (fig. 1). Conceivably, if the methylated metabolites contribute to the in vivo TrkB agonistic effect by 7,8-DHF, it might mainly result from the 8-methoxy-7-hydroxyflavone metabolite. Nonetheless, the parent compound concentrations in the brain are approximately 30-fold higher than those of the methylated metabolite, indicating that the main contribution to triggering TrkB activation results from the parent compound. It is worth noting that TrkB activation is demonstrable at 4 h or more in mouse brain after oral dosing of 7,8-DHF [14], suggesting that at later time points, TrkB activation may be predominantly triggered by 7,8-DHF itself. At early time points, such as 1–2 h, the methylated metabolite 8-methoxy-7-hydroxyflavone may also contribute to TrkB activation in the brain, which is supported by the COMT inhibitor data, and they show partial blockage of the agonistic effect by 7,8-DHF in mouse brain (fig. 4). After oral administration, a portion of 7,8-DHF is metabolized through O-glucuronidation in the circulation system (O-sulfation on 7,8-DHF was also detected with much lower concentrations in the plasma), lowering its drug exposure in the CNS. The parent drug and methylated metabolites penetrate the BBB, where they both activate the TrkB receptor. Blockage of 7,8-DHF O-mono-methylation via inhibiting COMT diminishes the effect of 7,8-DHF on TrkB activation (fig. 7).

After 7,8-DHF has been administered to animals, it enters the brain, where it may crosstalk with endogenous BDNF to provoke TrkB receptor activation in the CNS. To explore whether these ligands affect each other’s actions on TrkB activation, we monitored TrkB receptor activation in primary neurons by BDNF in the presence or absence of 7,8-DHF. Titration assay showed that BDNF elicited TrkB activation at a concentration of 1–30 nmol/l and the signals escalated as the doses increased (online suppl. fig. 2A). On the other hand, 7,8-DHF also stimulated TrkB activation in a dose-dependent manner. TrkB phosphorylation was prominent at a concentration of 100 nmol/l [14, 23]. Remarkably, when 3 nmol/l BDNF was mixed with various concentrations of 7,8-DHF, the mixture displayed much higher TrkB phosphorylation signals than when the same dose of BDNF or 7,8-DHF was employed separately (online suppl. fig. 2B). Therefore, there is a synergistic effect between 7,8-DHF and BDNF in provoking TrkB receptor activation. Conceivably, these two molecules bind to different sites on TrkB extracellular domain and trigger an optimal TrkB activation conformation, leading to higher TrkB activation signals than when these molecules interact independently with the receptor.

Levodopa, a precursor of catecholamines, is an important substrate of COMT. COMT inhibitors, like entacapone, protect levodopa from COMT, which prolongs the action of levodopa. Entacapone is a widely used adjunct drug of levodopa therapy. When given with an inhibitor of dopa decarboxylase (carbidopa or benserazide), levodopa is protected further. This ‘triple therapy’ is becoming a standard in the treatment of Parkinson’s disease.
Remarkably, we noticed that entacapone or tolcapone pretreatment elicited a higher TrkB phosphorylation baseline than vehicle control, indicating that these COMT inhibitors themselves might somehow induce TrkB activation in mouse brain, concealing the agonistic effect by 7,8-DHF or the lead compound 4′-DMA-7,8-DHF (fig. 3). It is not surprising that both COMT inhibitors somehow elevate TrkB activation in mouse brain, because both of them contain the catechol group as does 7,8-DHF. In addition, our previous structure-activity relationship study shows that the catechol group in 7,8-DHF mediates its TrkB agonistic effect [14]. We found that 6,7-dihydroxyflavone and 6,7,3′-trihydroxyflavone but not 5,6-dihydroxyflavone or 5,7-dihydroxyflavone possess a TrkB agonistic effect, suggesting that para- and meta-positions of dihydroxy groups on the A ring relative to the ketone group in the C ring of flavonoids are critical for stimulating the TrkB receptor [14]. These chemical structure characteristics are well in alignment with the backbone structure of tolcapone. Although entacapone does not contain the ketone group attached to the nitrocatechol functional group, it contains the highly conjugated structures, similar to the conjugated B and C rings in flavone compounds.

So far, a few small peptides and compounds have been reported to activate the TrkB receptor and might act as TrkB agonists [24, 25]. Nonetheless, these molecules do not fully imitate BDNF or regulate TrkB physiological functions in animals. However, our lead compound 7,8-DHF has been extensively demonstrated to mimic BDNF and exert a variety of neurological actions in numerous models including PD, stroke [12], depression [13, 14, 26], learning and memory [27, 28]. Chronic treatment with 7,8-DHF reveals no demonstrable toxicity, supporting safety at a dose of 5 mg/kg [14]. In addition, most recently, it has been shown to stimulate the LTP in aged rats through the TrkB receptor [29]. Notably, this compound exhibits therapeutic efficacy in a mouse model of Rett syndrome, which is caused by mutations in MeCP2, leading to reduced levels of BDNF in the brain [30]. Taken together, this evidence supports the notion that 7,8-DHF indeed mimics BDNF and possesses more prominent physiological activities in various animal models than other reported peptidomimetics or small molecules, supporting the fact that 7,8-DHF is a superior compound, with oral bioavailability, for TrkB agonist drug development.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by grants from the National Institute of Health RO1 DC010204 to K. Ye. The authors are grateful to Dr. Obianyo in the lab of Dr. Ye and to Dr. Harish Joshi for critically reading the manuscript.

References


Fig. 1.
In vivo pharmacokinetic profiling study of 7,8-DHF. Concentration-time profiles of 7,8-DHF and its metabolite 8-hydroxy-7-methoxyflavone (H428) and the isomer of 7-hydroxy-8-methoxyflavone (RT 2.92) in plasma and brain were analyzed by LC/MS/MS after oral administration (50 mg/kg) to mice with 7,8-DHF.
Fig. 2. Metabolite identification in mouse plasma. 

- **a** Selected reaction monitoring of 269.2 m/z precursor ion in plasma and brain samples after oral dosing of 50 mg/kg 7,8-DHF.
- **b** Product ion scan using 269.2 m/z precursor ion of 8-hydroxy-7-methoxyflavone (H428).
- **c, d** Product ion scan using 269.2 m/z precursor ion of the spectrum peak of 2.92 (7-hydroxy-8-methoxyflavone) from plasma and brain samples.
Fig. 3.
The methylated metabolite H428 activates TrkB receptor in vitro and in vivo. 

a Chemical structures of 7,8-DHF and various methylated derivatives.

b Methylated 7,8-DHF derivatives activate TrkB receptor in primary neurons. The primary cortical neurons (DIV12) from E17 rat embryos were treated with 500 nmol/l of various chemicals for 15 min. The control was treated with the same volume of vehicle DMSO/PBS. The neuronal lysates were subjected to SDS-PAGE, followed by immunoblotting with anti-p-TrkB Y816 and anti-TrkB (cell signaling) (upper panels). BDNF, a positive control, and lead compound Liu et al. Page 17

Pharmacology, Author manuscript; available in PMC 2016 March 16.
4′-DMA-7,8-DHF activated TrkB receptor signaling pathways in primary neurons (lower panel). c, d. 7,8-DHF and its methylated derivatives activate TrkB receptor in mouse brain. Two-month-old C57BL/6J mice were treated with 5 mg/kg of 7,8-DHF, H428, and D024 via oral gavage. Within 2 h, mice were sacrificed and brain samples were extracted and analyzed by immunoblotting with anti-p-TrkB 816 antibody and by p-Akt monitoring ELISA (c). 4′-DMA-7,8-DHF and its methylated derivatives were administrated to the mice at 1 mg/kg, the brain samples were prepared at 2 h, and the brains were analyzed by immunoblotting and p-Akt ELISA (d). * p < 0.05; ** p < 0.01; *** p < 0.001.
Fig. 4. Inhibition of methylation by COMT inhibitors reduces TrkB activation by 7,8-DHF or 4′-DMA-7,8-DHF. a COMT inhibitors decrease the agonistic effect of 7,8-DHF and 4′-DMA-7,8-DHF on TrkB signaling. Two-month-old C57BL/6J mice were treated with 30 mg/kg of entacapone (Ent) or tolcapone (Tol) 1 h before 5 mg/kg of 7,8-DHF and 4′-DMA-7,8-DHF via oral gavage. Within 2 h, mice were sacrificed and brain samples were extracted and analyzed by immunoblotting (left panels). Entacapone but not tolcapone decreases TrkB phosphorylation signals by COMT inhibitors, 10 mg/kg of COMT inhibitors were administered. The brain samples were analyzed as indicated above (middle panels). The
quantification of p-TrkB versus total TrkB was analyzed (right panels) (one-way ANOVA, n = 3; * p < 0.01, ** p < 0.001 vs. control). COMT inhibitors decrease the Akt activation by 7,8-DHF and 4′-DMA-7,8-DHF in brain at 30 mg/kg. Quantitative analysis of brain samples by p-Akt ELISA. Data are presented as mean ± SEM (one-way ANOVA, n = 4; * p < 0.01 vs. control). WT = Wild-type; Ct = control.
Chronic treatment with methylated derivatives displays a robust antidepressant effect. 

**a** Organic synthesis of methylated derivatives of flavonoids. 

**b** TrkB receptor activation by synthetic compounds C and D in vivo. The synthetic methylated compounds activate TrkB receptor in mouse brain after oral administration with 1 mg/kg dose at 2 h. 

**c** The methylated derivatives significantly reduce immobility in two antidepressant behavioral assays. Male C57/BL/6J mice (8 mice/group) were orally administrated by gavage with 5 mg/kg H428, compounds C and D and vehicle solvent saline for 21 days and subjected to a FST (6 min, immobility recorded in the last 4 min with 2 min preswim). Data are presented as mean ± SEM. ANOVA revealed a significant difference between vehicle and either of the employed compounds (n = 8, **p < 0.001 vs. vehicle) (left panel). The mice were subjected to the same treatment and analyzed by TST (6 min, immobility recorded in the last 4 min with 2 min preswim). Data are presented as mean ± SEM. ANOVA revealed a significant difference between vehicle and either of the employed compounds (n = 8, **p < 0.001 vs. vehicle) (right panel). 

**d** Locomotor activity assay. Compound D but not compound C or H428 significantly elevated the mice locomotor activity compared to vehicle control after 21 days of chronic treatment. RT = Room temperature. *p < 0.05; **p < 0.01.
Fig. 6. Chronic treatment with methylated derivatives promotes neurogenesis and TrkB activation in the hippocampus. a Neurogenesis assay via BrdU incorporation. Male C57BL/6J mice were orally administered with 5 mg/kg of various methylated compounds and vehicle solvent for 21 days and followed by 50 mg/kg BrdU i.p. Within 2 h, the mice were perfused and brain sections were immunostained with anti-BrdU to monitor the neuronal proliferation phase and DAPI. The positive cells in the dentate gyrus are highlighted by arrows. b Quantitative analysis of the BrdU-positive cells in the dentate gyrus (DG). Data are
presented as mean ± SEM (* p < 0.05 vs. vehicle, Student’s t test). c Immunohistochemistry staining of brain sections. Methylated derivatives upregulate TrkB activation in the dentate gyrus. Paraffin sections were deparaffinized in xylene and rehydrated by a gradient ethanol solution. Samples were boiled in 10 mmol/l sodium citrate buffer for 20 min to retrieve antigen. Brain sections were incubated with anti-TrkB (BD Biosciences) 1: 50, and anti-p-TrkB Y816 was used at 1: 300 dilution.
Fig. 7.
The schematic model for 7,8-DHF and its methylated metabolites to activate TrkB in brain. The orally administered 7,8-DHF is mainly metabolized via glucuronidation and methylation. In the plasma both types of modified metabolites and parent 7,8-DHF were detectable, whereas in brain only 7,8-DHF and 8-mono-methylated metabolite could be demonstrated. Both 7,8-DHF and its methylated metabolite provoked TrkB activation in mouse brain. The blockade of COMT transferase inhibits the methylation of 7,8-DHF and reduces the agonistic activity by 7,8-DHF in mouse brain.
Table 1

In vivo pharmacokinetic parameters of 7,8-DHF (p.o. 50 mg/kg)

<table>
<thead>
<tr>
<th>Cerep compound ID (dosed)</th>
<th>Client compound ID (dosed)</th>
<th>Route of administration</th>
<th>Dose mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>100002126-1</td>
<td>7,8-DHF</td>
<td>p.o.</td>
<td>50</td>
</tr>
</tbody>
</table>

| Cerep compound ID (detected) | Client compound ID (detected) | Subject | $T_{\text{max}}$ min | $C_{\text{max}}$ ng/ml | $T_{1/2}$ min | $AUC_{\text{last}}^{-1}$ min·ng/ml | $AUC_{\text{Inf}}^{-1}$ min·ng/ml | Terminal point |
|-----------------------------|-------------------------------|---------|----------------------|------------------------|---------------|-----------------------------------|-----------------------------------|----------------|-------------|
| 100002126-1                 | 7,8-DHF                       | mice    | 10                   | 70                     | 134           | 6,500                             | 7,515                             | 7              |
| 100002126-2                 | 8-hydroxy-7-methoxyflavone    | mice    | 10                   | 1                      | 92            | 80                                | 100                               | 5              |

Pharmacokinetic parameters were derived from the noncompartmental model using WinNonlin 5.2.

$T_{\text{max}}$ = Time of maximum observed concentration; $C_{\text{max}}$ = concentration corresponding to $T_{\text{max}}$; $T_{1/2}$ = elimination half-life; $AUC_{\text{last}}$ = area under the concentration-time curve from the time of dosing to the time of last observation that is greater than the limit of quantitation; $AUC_{\text{Inf}}$ = area under the concentration-time curve from the time of dosing, extrapolated to infinity; terminal point = number of observations used to calculate the terminal slope.

$^{-1}$ Linear/log trapezoidal method was used for AUC calculation.
Table 2

In vitro Caco-2 permeability assay for 7,8-DHF and 4'-DMA-7,8-DHF

<table>
<thead>
<tr>
<th>Client ID</th>
<th>Test conc. μmol/l</th>
<th>Assay duration, h</th>
<th>Mean A→B $P_{app}$ $10^{-6}$ cm•s$^{-1}$</th>
<th>Mean B→A $P_{app}$ $10^{-6}$ cm•s$^{-1}$</th>
<th>Efflux ratio</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranitidine</td>
<td>10</td>
<td>2</td>
<td>0.3</td>
<td>2.9</td>
<td>10.9</td>
<td>low permeability, efflux</td>
</tr>
<tr>
<td>Warfarin</td>
<td>10</td>
<td>2</td>
<td>52.6</td>
<td>18.3</td>
<td>0.3</td>
<td>high permeability control</td>
</tr>
<tr>
<td>4'-DMA-7,8-DHF</td>
<td>10</td>
<td>2</td>
<td>0.9</td>
<td>3.1</td>
<td>3.6</td>
<td>poor recovery A to B</td>
</tr>
<tr>
<td>7,8-DHF</td>
<td>10</td>
<td>2</td>
<td>1.5</td>
<td>1.7</td>
<td>1.2</td>
<td>poor recovery A to B</td>
</tr>
</tbody>
</table>

$P_{app}$ = Apparent permeability.

$^f$ Efflux ratio ($R_E$) >2 indicates significant efflux activity, an indication of a potential substrate for PGP or other active transporters.